Buscar
Mostrando ítems 1-10 de 11
Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2011)
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance ...
Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula ÓsseaBrasil, 2011)
Patients’ Perceptions About Diagnosis And Treatment Of Chronic Myeloid Leukemia: A Cross-sectional Study Among Brazilian Patients [percepções Dos Pacientes Sobre Diagnóstico E Tratamento Da Leucemia Mieloide Crônica: Estudo Transversal Entre Pacientes Brasileiros]
(Associacao Paulista de Medicina, 2015)